The NICE guideline Delirium: prevention, diagnosis and management (CG103) has been checked by NICE for the need for update.
Registered stakeholders for the guideline are invited to comment on the provisional decision via this website.
If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.
Not eligible? Contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them.
We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.
Note that the provisional review decision presented here does not constitute NICE's formal decision on this guideline. The decision is provisional and may change after consultation.
Consultation dates: Friday, 31 August 2018 (9am) to Thursday, 13 September 2018 (5pm)
Consultation documents:
How to submit your comments:
Please provide all responses to the review proposal document using the comments form (ensuring all relevant fields are completed, including your organisation’s full name) and forward this by email before 5pm on Thursday, 13 September 2018 to the following email address:
NICE is unable to accept:
- Comments from non-registered organisations – if you wish your comments to be considered please register via the NICE website
- Comments received after the consultation deadline (5pm)
- Comments that are not on the correct form
- More than one response per stakeholder organisation
- Confidential information or other material that you would not wish to be made public
- Personal medical information about yourself or another person from which your or the person’s identity could be ascertained.
What will happen to your comments?
- Comments from registered stakeholders and nominated expert reviewers ONLY will be sent to the review team at the end of the consultation. These will inform the final decision made by the NICE Guidance Executive.
- No action will be taken upon receipt of personal, comments from non-registered organisations and late comments.
Anticipated review decision publication date: November 2018
Further information:
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Appendix D diagnostic test accuracy - included studies (PDF 182 KB)
-
-
Appendix D non pharmacological risk factors - included studies (PDF 90 KB)
-
Appendix D pharmacological risk factors - included studies (PDF 49 KB)
-
Appendix E consequences of cohort studies - methodological quality (PDF 125 KB)
-
Appendix E diagnostic accuracy tests - methodological quality (PDF 172 KB)
-
Appendix E epidemiology - methodological quality (PDF 168 KB)
-
Appendix E non-pharmacological risk factors cohort studies - methodological quality (PDF 44 KB)
-
Appendix E pharmacological risk factors cohort studies - methodological quality (PDF 29 KB)
-
Appendix E patient information - methodological quality (PDF 213 KB)
-
Appendix F consequences of - multivariate risk factors (PDF 185 KB)
-
Appendix F - non-pharmacological risk factors - multivariate risk factors (PDF 293 KB)
-
Appendix F pharmacological risk factors - multivariate risk factors (PDF 63 KB)
-
Appendix G diagnostic test accuracy - excluded studies (PDF 128 KB)
-
Appendix G adverse effects review - excluded studies (PDF 121 KB)
-
-
Appendix G epidemiology review - excluded studies (PDF 146 KB)
-
Appendix G non-pharmacological risk factors - excluded studies (PDF 71 KB)
-
Appendix G information for patients review - excluded studies (PDF 118 KB)
-
Appendix G pharmacological risk factors - excluded studies (PDF 55 KB)
-
-
-
-
-
Consultation table and with developers responses (PDF 1.02 MB)
-
Pre-publication check - stakeholder comments/developer responses (PDF 49 KB)
-
-
-
-
-
Appendix D - Adverse Effects - Included studies (PDF 121 KB)
-
Appendix D - Consequences of - Included studies (PDF 155 KB)
-
Appendix D - Diagnostic Test Accuracy - Included Studies (PDF 182 KB)
-
-
Appendix D - Non pharmacological Risk factor - Included studies (PDF 44 KB)
-
Appendix D - Pharma Nonpharma Prevention Treatment - Included studies (PDF 170 KB)
-
Appendix D - Pharmacological Risk factors - Included studies (PDF 49 KB)
-
-
Appendix E - Diagnostic Accuracy Tests Methodological Quality (PDF 172 KB)
-
-
-
-
Appendix E - Pharma NonPharma Prevention Treatment (PDF 107 KB)
-
Appendix E - Pharmacological Risk Factors review - Randomised controlled trials (PDF 23 KB)
-
Appendix E - Pharmacological Risk Factors review - cohort studies (PDF 30 KB)
-
-
Appendix H - Recommendations for Future Research (PDF 75 KB)
-
-
-
-
Consultation table and with developers responses (PDF 1.02 MB)
This page was last updated: